Finoriq

Finoriq research workspace

DEXCOM INC (DXCM) SEC Filings & Filing Highlights

DEXCOM INC offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system. Review DXCM SEC filings, filing highlights, and disclosure activity on Finoriq.

Company Snapshot

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Company
DEXCOM INC (DXCM)
Ticker
DXCM
Market Cap
$29.3B
Latest Price
$75.88
Industry
Medical Devices

Open insider transactions

DEXCOM INC (DXCM) Recent SEC Filing Highlights

Recent SEC filings, filing events, and disclosure highlights indexed for DEXCOM INC (DXCM).

EventFormDate
DEXCOM INC: Shareholder voteOn May 27, 2026, DexCom, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the close of business...8-K5.072026-05-28
Cautionary Statement Regarding Forward Looking StatementsOn May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of D...8-K8.012026-05-15
In addition, Dexcom announced new long-range financial targets at its 2026 Investor Day at the...In addition, Dexcom announced new long-range financial targets at its 2026 Investor Day at the following levels8-K7.012026-05-15
Dexcom Reports First Quarter 2026 Financial ResultsDexcom Reports First Quarter 2026 Financial Results8-K2.022026-04-30
As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer...As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board...8-K5.022026-03-02

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.